Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):495–503. doi: 10.1038/sj.bjc.6690384

Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer

M N Holten-Andersen 1, G Murphy 2, H J Nielsen 4, A N Pedersen 1,3, I J Christensen 1, G Høyer-Hansen 1, N Brünner 1, R W Stephens 1
PMCID: PMC2362309  PMID: 10408859

Abstract

A kinetic enzyme-linked immunosorbent assay (ELISA) for plasma tissue inhibitor of metalloproteinase (TIMP)-1 was developed in order to examine the potential diagnostic and prognostic value of TIMP-1 measurements in cancer patients. The ELISA enabled specific detection of total TIMP-1 in EDTA, citrate and heparin plasma. The assay was rigorously tested and requirements of sensitivity, specificity, stability and good recovery were fulfilled. TIMP-1 levels measured in citrate plasma (mean 69.2 ± 13.1 μg l−1) correlated with TIMP-1 measured in EDTA plasma (mean 73.5 ± 14.2 μg l−1) from the same individuals in a set of 100 healthy blood donors (Spearman's rho = 0.62, P < 0.0001). The mean level of TIMP-1 in EDTA plasma from 143 patients with Dukes' stage D colorectal cancer was 240 ± 145 μg l−1 and a Mann–Whitney test demonstrated a highly significant difference between TIMP-1 levels in healthy blood donors and colorectal cancer patients (P < 0.0001). Similar findings were obtained for 19 patients with advanced breast cancer (mean 292 ± 331 μg l−1). The results show that TIMP-1 is readily measured in plasma samples by ELISA and that increased levels of TIMP-1 are found in patients with advanced cancer. It is proposed that plasma measurements of TIMP-1 may have value in the management of cancer patients. © 1999 Cancer Research Campaign

Keywords: TIMP-1, ELISA, plasma, cancer, blood donors

Full Text

The Full Text of this article is available as a PDF (156.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker T., Tickle S., Wasan H., Docherty A., Isenberg D., Waxman J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer. 1994 Sep;70(3):506–512. doi: 10.1038/bjc.1994.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Birkedal-Hansen H., Moore W. G., Bodden M. K., Windsor L. J., Birkedal-Hansen B., DeCarlo A., Engler J. A. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4(2):197–250. doi: 10.1177/10454411930040020401. [DOI] [PubMed] [Google Scholar]
  3. Clark I. M., Powell L. K., Wright J. K., Cawston T. E. Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix. 1991 Apr;11(2):76–85. doi: 10.1016/s0934-8832(11)80211-8. [DOI] [PubMed] [Google Scholar]
  4. Cooksley S., Hipkiss J. B., Tickle S. P., Holmes-Ievers E., Docherty A. J., Murphy G., Lawson A. D. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix. 1990 Oct;10(5):285–291. doi: 10.1016/s0934-8832(11)80183-6. [DOI] [PubMed] [Google Scholar]
  5. Cooper T. W., Eisen A. Z., Stricklin G. P., Welgus H. G. Platelet-derived collagenase inhibitor: characterization and subcellular localization. Proc Natl Acad Sci U S A. 1985 May;82(9):2779–2783. doi: 10.1073/pnas.82.9.2779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. De Nictolis M., Garbisa S., Lucarini G., Goteri G., Masiero L., Ciavattini A., Garzetti G. G., Stetler-Stevenson W. G., Fabris G., Biagini G. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study. Int J Gynecol Pathol. 1996 Apr;15(2):102–109. doi: 10.1097/00004347-199604000-00003. [DOI] [PubMed] [Google Scholar]
  7. DeClerck Y. A., Perez N., Shimada H., Boone T. C., Langley K. E., Taylor S. M. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992 Feb 1;52(3):701–708. [PubMed] [Google Scholar]
  8. Deng G., Curriden S. A., Wang S., Rosenberg S., Loskutoff D. J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol. 1996 Sep;134(6):1563–1571. doi: 10.1083/jcb.134.6.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fong K. M., Kida Y., Zimmerman P. V., Smith P. J. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res. 1996 Aug;2(8):1369–1372. [PubMed] [Google Scholar]
  10. Fujimoto N., Zhang J., Iwata K., Shinya T., Okada Y., Hayakawa T. A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. Clin Chim Acta. 1993 Oct 29;220(1):31–45. doi: 10.1016/0009-8981(93)90004-n. [DOI] [PubMed] [Google Scholar]
  11. Gohji K., Fujimoto N., Fujii A., Komiyama T., Okawa J., Nakajima M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res. 1996 Jul 15;56(14):3196–3198. [PubMed] [Google Scholar]
  12. Goldberg G. I., Strongin A., Collier I. E., Genrich L. T., Marmer B. L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem. 1992 Mar 5;267(7):4583–4591. [PubMed] [Google Scholar]
  13. Hayakawa T., Yamashita K., Tanzawa K., Uchijima E., Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992 Feb 17;298(1):29–32. doi: 10.1016/0014-5793(92)80015-9. [DOI] [PubMed] [Google Scholar]
  14. Hembry R. M., Murphy G., Reynolds J. J. Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum. J Cell Sci. 1985 Feb;73:105–119. doi: 10.1242/jcs.73.1.105. [DOI] [PubMed] [Google Scholar]
  15. Jung K., Nowak L., Lein M., Henke W., Schnorr D., Loening S. A. Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin Chem. 1996 Dec;42(12):2043–2045. [PubMed] [Google Scholar]
  16. Jung K., Nowak L., Lein M., Henke W., Schnorr D., Loening S. A. What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood? Clin Chim Acta. 1996 Oct 15;254(1):97–100. doi: 10.1016/0009-8981(96)06367-x. [DOI] [PubMed] [Google Scholar]
  17. Kawano N., Osawa H., Ito T., Nagashima Y., Hirahara F., Inayama Y., Nakatani Y., Kimura S., Kitajima H., Koshikawa N. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol. 1997 May;28(5):613–622. doi: 10.1016/s0046-8177(97)90085-x. [DOI] [PubMed] [Google Scholar]
  18. Khokha R., Waterhouse P. The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. J Neurooncol. 1994;18(2):123–127. doi: 10.1007/BF01050418. [DOI] [PubMed] [Google Scholar]
  19. Khokha R., Zimmer M. J., Graham C. H., Lala P. K., Waterhouse P. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst. 1992 Jul 1;84(13):1017–1022. doi: 10.1093/jnci/84.13.1017. [DOI] [PubMed] [Google Scholar]
  20. Khokha R., Zimmer M. J., Wilson S. M., Chambers A. F. Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis. 1992 Nov;10(6):365–370. doi: 10.1007/BF00133464. [DOI] [PubMed] [Google Scholar]
  21. Kleiner D. E., Jr, Tuuttila A., Tryggvason K., Stetler-Stevenson W. G. Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry. 1993 Feb 16;32(6):1583–1592. doi: 10.1021/bi00057a024. [DOI] [PubMed] [Google Scholar]
  22. Kodama S., Yamashita K., Kishi J., Iwata K., Hayakawa T. A sandwich enzyme immunoassay for collagenase inhibitor using monoclonal antibodies. Matrix. 1989 Jan;9(1):1–6. doi: 10.1016/s0934-8832(89)80011-3. [DOI] [PubMed] [Google Scholar]
  23. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991 Jan 25;64(2):327–336. doi: 10.1016/0092-8674(91)90642-c. [DOI] [PubMed] [Google Scholar]
  24. MacDougall J. R., Matrisian L. M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 1995 Dec;14(4):351–362. doi: 10.1007/BF00690603. [DOI] [PubMed] [Google Scholar]
  25. Matrisian L. M. The matrix-degrading metalloproteinases. Bioessays. 1992 Jul;14(7):455–463. doi: 10.1002/bies.950140705. [DOI] [PubMed] [Google Scholar]
  26. Mimori K., Mori M., Shiraishi T., Fujie T., Baba K., Haraguchi M., Abe R., Ueo H., Akiyoshi T. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997;76(4):531–536. doi: 10.1038/bjc.1997.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Moll U. M., Youngleib G. L., Rosinski K. B., Quigley J. P. Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Res. 1990 Oct 1;50(19):6162–6170. [PubMed] [Google Scholar]
  28. Moutsiakis D., Mancuso P., Krutzsch H., Stetler-Stevenson W., Zucker S. Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect Tissue Res. 1992;28(3):213–230. doi: 10.3109/03008209209015038. [DOI] [PubMed] [Google Scholar]
  29. Murphy G., Houbrechts A., Cockett M. I., Williamson R. A., O'Shea M., Docherty A. J. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry. 1991 Aug 20;30(33):8097–8102. doi: 10.1021/bi00247a001. [DOI] [PubMed] [Google Scholar]
  30. Nuovo G. J., MacConnell P. B., Simsir A., Valea F., French D. L. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 1995 Jan 15;55(2):267–275. [PubMed] [Google Scholar]
  31. Stetler-Stevenson W. G., Hewitt R., Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol. 1996 Jun;7(3):147–154. doi: 10.1006/scbi.1996.0020. [DOI] [PubMed] [Google Scholar]
  32. Stetler-Stevenson W. G., Krutzsch H. C., Liotta L. A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem. 1989 Oct 15;264(29):17374–17378. [PubMed] [Google Scholar]
  33. Stetler-Stevenson W. G., Liotta L. A., Kleiner D. E., Jr Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993 Dec;7(15):1434–1441. doi: 10.1096/fasebj.7.15.8262328. [DOI] [PubMed] [Google Scholar]
  34. Thorgeirsson U. P., Lindsay C. K., Cottam D. W., Gomez D. E. Tumor invasion, proteolysis, and angiogenesis. J Neurooncol. 1994;18(2):89–103. doi: 10.1007/BF01050415. [DOI] [PubMed] [Google Scholar]
  35. Welgus H. G., Jeffrey J. J., Eisen A. Z., Roswit W. T., Stricklin G. P. Human skin fibroblast collagenase: interaction with substrate and inhibitor. Coll Relat Res. 1985 Mar;5(2):167–179. doi: 10.1016/s0174-173x(85)80038-8. [DOI] [PubMed] [Google Scholar]
  36. Wilhelm S. M., Collier I. E., Marmer B. L., Eisen A. Z., Grant G. A., Goldberg G. I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem. 1989 Oct 15;264(29):17213–17221. [PubMed] [Google Scholar]
  37. Yoshiji H., Gomez D. E., Thorgeirsson U. P. Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int J Cancer. 1996 Apr 22;69(2):131–134. doi: 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  38. Zucker S., Lysik R. M., DiMassimo B. I., Zarrabi H. M., Moll U. M., Grimson R., Tickle S. P., Docherty A. J. Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer. 1995 Aug 15;76(4):700–708. doi: 10.1002/1097-0142(19950815)76:4<700::aid-cncr2820760426>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES